Can neoadjuvant chemotherapy change clinic pathological and survival parameters in HER-2 positive breast cancer patients?

被引：0
|
作者：
Mundim, F. [1 ]
Franco, A. [1 ]
Infante, K. [1 ]
Neto, J. [1 ]
Brentani, M. M. [1 ]
Facina, G. [1 ]
Waitzberg, A. [1 ]
机构：
[1] Univas Brazil, Pathol, Pouso Alegre, Brazil
来源：
VIRCHOWS ARCHIV | 2018年 / 473卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-02-04
引用
收藏
页码：S209 / S209
页数：1
相关论文
共 50 条
  • [41] Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients
    Guan, Dandan
    Shi, Qingyang
    Zheng, Yajuan
    Zheng, Chaopeng
    Meng, Xuli
    CLINICAL BREAST CANCER, 2024, 24 (05) : 463 - 472.e2
  • [42] Impact of HER2 Overexpression and Coexpression of Hormonal Receptors on Pathological Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
    Moscoso, Louis
    Ruiz-Merino, Guadalupe
    Salazar Huayna, Lourdes
    Iborra-Lacal, Emma
    Escriva de Romani, Santiago
    Jimenez-Lucas, Maria
    Siso Raber, Christian
    Cabezas-Herrera, Juan
    Peg, Vicente
    Ramon Y Cajal, Santiago
    Pinero-Madrona, Antonio
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 168 - 169
  • [43] Impact of HER2 Overexpression and Coexpression of Hormonal Receptors on Pathological Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
    Moscoso, Louis
    Ruiz-Merino, Guadalupe
    Huayna, Lourdes Salazar
    Iborra-Lacal, Emma
    de Romani, Santiago Escriva
    Jimenez-Lucas, Maria
    Raber, Christian Siso
    Cabezas-Herrera, Juan
    Peg, Vicente
    Ramon Y Cajal, Santiago
    Pinero-Madrona, Antonio
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 168 - 169
  • [44] Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
    Rodriguez, Mauricio
    Gonzalez, Diego M.
    El-Sharkawy, Farah
    Castano, Mileny
    Madrid, Jorge
    BIOMEDICA, 2023, 43 (03): : 396 - 405
  • [45] HER-2 and choice of adjuvant chemotherapy in breast cancer
    Paik, S
    Park, C
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 332 - 335
  • [46] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [47] Prediction of response to neoadjuvant chemotherapy in HER2 positive breast cancer by MammaTyper®
    Scatena, C.
    Belcastro, E.
    Scarpitta, R.
    Naccarato, A. G.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 30 - 30
  • [48] Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
    Palmieri, Carlo
    Macpherson, Iain R. J.
    Yan, Kelvin
    Ades, Felipe
    Riddle, Pippa
    Ahmed, Riz
    Owadally, Waheeda
    Stanley, Barbara
    Shah, Deep
    Gojis, Ondrej
    Januszewski, Adam
    Lewanski, Conrad
    Asher, Rebecca
    Lythgoe, Daniel
    de Azambuja, Evandro
    Beresford, Mark
    Howell, Sacha J.
    ONCOTARGET, 2016, 7 (11) : 13209 - 13220
  • [49] A predictor model for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
    Fujiki, Yoshitaka
    Yamamoto, Yutaka
    Tomiguchi, Mai
    Sueta, Aiko
    Takeshita, Takashi
    Ibusuki, Mutsuko
    Iwase, Hirotaka
    CANCER SCIENCE, 2018, 109 : 654 - 654
  • [50] A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
    Piras, Marta
    Panebianco, Martina
    Garibaldi, Matteo
    Roberto, Michela
    Merlonghi, Gioia
    Pellegrini, Patrizia
    Marchetti, Paolo
    CURRENT ONCOLOGY, 2021, 28 (03) : 1957 - 1961
12345